SLC29A1 and Huntington disease: Previously, JMF1907, an adenosine analog, has been demonstrated to be ENT-1 inhibitor that can increase brain extracellular adenosine levels in the striatum of mice by intraperitoneal administration and produces beneficial effects on transgenic mice with Huntington disease (HD) (Kao et al., 2017).